Cargando…

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers

Background: There has been evidence that Polybromo-1 (PBRM1) mutation was closely associated with immunotherapy response in clear cell renal cell carcinoma (ccRCC). However, it remains incompletely unclear whether PBRM1 mutations correlate with ICI response in pan-cancer. Methods: The clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Jiali, Cui, Yanan, Liang, Xiao, Xu, Jiali, Li, Jun, Chen, Yu, Zhang, Erbao, Guo, Renhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868445/ https://www.ncbi.nlm.nih.gov/pubmed/36699446 http://dx.doi.org/10.3389/fgene.2022.1066347

Ejemplares similares

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma
por: Cui, Yanan, et al.
Publicado: (2023)

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
por: Aili, Abudureyimujiang, et al.
Publicado: (2021)

LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer
por: Dai, Jiali, et al.
Publicado: (2023)

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
por: Dai, Jiali, et al.
Publicado: (2023)

STAT6, PBX2, and PBRM1 Emerge as Predicted Regulators of 452 Differentially Expressed Genes Associated With Puberty in Brahman Heifers
por: Nguyen, Loan T., et al.
Publicado: (2018)

Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates
por: Yang, Qiuan, et al.
Publicado: (2021)

Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
por: Liu, Xingyu, et al.
Publicado: (2020)

Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes
por: Yu, Lishan, et al.
Publicado: (2022)

An efficient five-lncRNA signature for lung adenocarcinoma prognosis, with AL606489.1 showing sexual dimorphism
por: Liang, Jiali, et al.
Publicado: (2022)

An integrative analysis of DNA methylation and gene expression to predict lung adenocarcinoma prognosis
por: Xu, Liexi, et al.
Publicado: (2022)

Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer
por: Guo, Yangyang, et al.
Publicado: (2023)

Immunotherapy response and microenvironment provide biomarkers of immunotherapy options for patients with lung adenocarcinoma
por: Zhan, Xue, et al.
Publicado: (2022)

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
por: Carril-Ajuria, Lucía, et al.
Publicado: (2019)

An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
por: Feng, Mingtao, et al.
Publicado: (2022)

Pyroptosis-Related Gene to Construct Prognostic Signature and Explore Immune Microenvironment and Immunotherapy Biomarkers in Bladder Cancer
por: Zhang, Xiangyu, et al.
Publicado: (2022)

PBRM1 Regulates Stress Response in Epithelial Cells
por: Porter, Elizabeth G., et al.
Publicado: (2019)

Corrigendum: Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer
por: Guo, Yangyang, et al.
Publicado: (2023)

Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB
por: Miao, Xia-ye, et al.
Publicado: (2022)

Editorial: Predictive short/long-term efficacy biomarkers and resistance mechanisms of CAR-T immunotherapy treatment
por: Cheng, Jiali, et al.
Publicado: (2023)

Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer
por: Zhang, Chen, et al.
Publicado: (2023)

Identification of Fatty Acid Metabolism-Related lncRNAs as Biomarkers for Clinical Prognosis and Immunotherapy Response in Patients With Lung Adenocarcinoma
por: Wang, Helin, et al.
Publicado: (2022)

Combination of Tumor Mutational Burden and Specific Gene Mutations Stratifies Outcome to Immunotherapy Across Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
por: Peng, Ying-Peng, et al.
Publicado: (2021)

ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma
por: Zhang, Shirong, et al.
Publicado: (2022)

A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity
por: Wang, Yanan, et al.
Publicado: (2022)

PBRM1 bromodomains associate with RNA to facilitate chromatin association
por: De Silva, Saumya M, et al.
Publicado: (2023)

The development and validation of a nomogram for predicting brain metastases in lung squamous cell carcinoma patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Zhang, Jingya, et al.
Publicado: (2021)

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
por: Varela, Ignacio, et al.
Publicado: (2011)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Identification of a novel cellular senescence-related signature for the prediction of prognosis and immunotherapy response in colon cancer
por: Dai, Longfei, et al.
Publicado: (2022)

Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy
por: Ma, Bo, et al.
Publicado: (2023)

FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis
por: Huang, Xing, et al.
Publicado: (2022)

Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma
por: Xu, Yue, et al.
Publicado: (2022)

Pbrm1 intrinsically controls the development and effector differentiation of iNKT cells
por: Wang, Xin, et al.
Publicado: (2022)

Ferroptosis-Related Gene Signature Predicts the Prognosis of Skin Cutaneous Melanoma and Response to Immunotherapy
por: Xu, Ziqian, et al.
Publicado: (2021)

PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway
por: Wang, HongKai, et al.
Publicado: (2017)

Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker
por: Zhang, Chi, et al.
Publicado: (2022)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Next-generation sequencing of a large uveal melanoma with whole genome doubling and a PBRM1 mutation
por: Ahmad, Tessnim R., et al.
Publicado: (2023)

Increased NFATC4 Correlates With Poor Prognosis of AML Through Recruiting Regulatory T Cells
por: Zhao, Chong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7cb9b4vhe0k3l3bq2tem3ghq03